Loading
A phase 2 trial of VS-7375, Cetuximab in pancreatic ductal adenocarcinoma, run by Verastem, Inc., now recruiting.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer is a phase 2 interventional study registered as NCT07644559 by Verastem, Inc., with 180 participants planned, started 2026-06-16 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS. No results are recorded here; the registry entry is the source.
Shares VS-7375, Verastem Oncology, Cetuximab.
Shares VS-7375, Verastem Oncology.
Shares VS-7375, Verastem Oncology, Cetuximab, Pancreatic ductal adenocarcinoma.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Metastatic pancreatic ductal adenocarcinoma.